Senti Biosciences, Inc.

Equities

SNTI

US81726A1007

Biotechnology & Medical Research

End-of-day quote Nasdaq 07:00:00 2024-03-25 pm EDT 5-day change 1st Jan Change
0.412 USD +0.98% Intraday chart for Senti Biosciences, Inc. -6.36% -37.58%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Senti Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (SNTI) SENTI BIOSCIENCES Reports 2023 Revenue $2.6M MT
Senti Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Spark Therapeutics, Inc. Announces Workforce Reduction CI
Top Premarket Gainers MT
Senti Biosciences, Inc. Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia CI
Senti Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (SNTI) SENTI BIOSCIENCES Posts Q3 Revenue $338,000 MT
Senti Biosciences, Inc. Announces New Strategic Collaboration with Celest Therapeutics Co. Ltd CI
Earnings Flash (SNTI) SENTI BIOSCIENCES Posts Q2 Revenue $937,000 MT
Senti Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Senti Biosciences, Inc. Announces Resignation of Philip Lee as Chief Technology Officer CI
GeneFab, LLC acquired Rights, title and interest in certain of the assets from Senti Biosciences, Inc. for $37.8 million. CI
Senti Biosciences, Inc. Highlights Initial Gene Circuit Data from Collaborations At the American Society of Gene and Cell Therapy Annual Meeting CI
Chardan Cuts Price Target on Senti Biosciences to $6 From $7, Keeps Buy Rating MT
Earnings Flash (SNTI) SENTI BIOSCIENCES Posts Q1 Revenue $1.3M MT
Senti Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Senti Biosciences, Inc. Highlights Preclinical Data from Multiple Gene Circuit Enabled Cell Therapy Programs At Annual American Association for Cancer Research Meeting CI
Morgan Stanley Adjusts Price Target on Senti Biosciences to $2 From $3, Keeps Equalweight Rating MT
Chardan Adjusts Price Target on Senti Biosciences to $7 From $8, Keeps Buy Rating MT
Earnings Flash (SNTI) SENTI BIOSCIENCES Reports Q4 Revenue $59,000 MT
Senti Biosciences, Inc. Announces Strategic Plan to Focus Research and Development Efforts on Lead Oncology Candidate SENTI-202 CI
Senti Biosciences, Inc. Auditor Raises 'Going Concern' Doubt CI
Senti Biosciences, Inc. Announces Three Preclinical Data Presentations from Gene Circuit-Enhanced CAR-NK Cell Oncology Pipeline at Annual AACR Meeting CI
Chardan Adjusts Senti Biosciences' Price Target to $8 From $12, Keeps Buy Rating MT
Chart Senti Biosciences, Inc.
More charts
Senti Biosciences, Inc. is a clinical-stage biotechnology company. It is developing cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. It is focused on off-the-shelf CAR-NK cell therapy programs for oncology indications. Its lead product candidate, SENTI-202, is a potential Logic Gated off-the-shelf CAR-NK cell therapy designed to selectively target and eliminate CD33 and/or FLT3 expressing hematologic malignancies, including acute myeloid leukemia, while sparing healthy bone marrow cells. Its second clinical development program is SENTI-301A, a multi-armed off-the-shelf healthy donor derived CAR-NK cell therapy. SENTI-202 has been designed to incorporate three chimeric proteins using a Logic Gated gene circuit and delivered through a single retrovirus. SENTI-301A is a multi-armed off-the-shelf healthy donor derived CAR-NK cell therapy designed for the treatment of advanced GPC3 positive tumors.
More about the company
  1. Stock
  2. Equities
  3. Stock Senti Biosciences, Inc. - Nasdaq
  4. News Senti Biosciences, Inc.
  5. Senti Biosciences Chief Operating Officer Curt Herberts Resigns